enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment
Rhea-AI Summary
enVVeno Medical (NASDAQ:NVNO) announced that CEO Robert Berman will appear in a Live Virtual Investor CEO Connect segment on Wednesday, December 3, 2025 at 4:00 PM ET. The moderated webcast will include a corporate overview, discussion of recent news and next steps, and a live Q&A where Mr. Berman will answer as many questions as time allows. A live video webcast will be available on the company Events page at www.envveno.com. A replay will be posted two hours after the live event and will remain accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NVNO declined 6.41%, reflecting a notable negative market reaction. Argus tracked a peak move of +14.8% during that session. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $548K from the company's valuation, bringing the market cap to $8M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NVNO was up 3.27% pre-event while several medical device peers (INBS, NXL, AIMD, ALUR) also showed gains and XAIR was down 0.9%. Mixed peer moves and scanner data showing only one momentum peer suggest this news was stock-specific rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Investor webcast | Neutral | -6.4% | Announcement of December 3 virtual investor CEO Connect webcast and Q&A. |
| Nov 13 | Regulatory setback | Negative | -5.2% | Unfavorable FDA supervisory appeal decision upholding not‑approvable letter for VenoValve. |
| Oct 31 | Earnings & update | Neutral | +1.1% | Q3 2025 results, cash runway into 2027, lower net loss, and regulatory update. |
| Sep 26 | Investor presentation | Neutral | +1.2% | Virtual investor segment explaining supervisory appeal after VenoValve not‑approvable letter. |
| Sep 15 | Regulatory update | Positive | +15.9% | Plan to file supervisory appeal and highlight of large CVI patient population and timeline. |
Across the last five announcements, NVNO’s price reaction usually aligned with the news tone, with only one notable divergence on a neutral investor-focused update.
Over the last few months, enVVeno moved from regulatory setbacks toward repositioning its pipeline. An unfavorable FDA appeal decision on VenoValve on Nov 13, 2025 followed earlier not‑approvable communications in August 2025, while Q3 results on Oct 31, 2025 highlighted cash of around $31 million and reduced net loss. Multiple investor webcasts in September and November 2025 focused on explaining these regulatory developments and next steps, providing context around the shift toward the enVVe program.
Market Pulse Summary
The stock moved -6.4% in the session following this news. A negative reaction despite this largely informational webcast announcement would echo the -6.41% move seen around the prior investor event on Nov 26, 2025. Historically, the stock tended to sell off more sharply on regulatory setbacks, such as the unfavorable FDA appeal decision at -5.16%. Given the stock’s distance from its $5.62 52-week high, reactions to communication events have shown limited durability.
AI-generated analysis. Not financial advice.
Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3rd at 4:00 PM ET
IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Live Virtual Investor CEO Connect segment on Wednesday, December 3, 2025 at 4:00 PM ET.
As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's recent news and next steps. In addition to the moderated discussion, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
###
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
FAQ
When will enVVeno Medical (NVNO) host the CEO Connect webcast with Robert Berman?
Where can investors watch the enVVeno Medical (NVNO) live webcast?
Will there be a recording of the enVVeno Medical (NVNO) CEO Connect event and how long will it be available?
What will CEO Robert Berman discuss during the enVVeno Medical (NVNO) presentation?
Can investors submit questions for enVVeno Medical (NVNO) CEO Robert Berman during the webcast?
